Brokerages forecast that Intersect ENT Inc (NASDAQ:XENT) will post ($0.17) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have made estimates for Intersect ENT’s earnings, with the lowest EPS estimate coming in at ($0.21) and the highest estimate coming in at ($0.12). Intersect ENT also reported earnings of ($0.17) per share during the same quarter last year. The business is expected to announce its next quarterly earnings results on Tuesday, February 27th.

On average, analysts expect that Intersect ENT will report full-year earnings of ($0.63) per share for the current fiscal year, with EPS estimates ranging from ($0.67) to ($0.57). For the next year, analysts expect that the business will report earnings of ($0.43) per share, with EPS estimates ranging from ($0.71) to ($0.23). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Intersect ENT.

Intersect ENT (NASDAQ:XENT) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.05. Intersect ENT had a negative return on equity of 15.96% and a negative net margin of 19.81%. The firm had revenue of $22.31 million for the quarter, compared to analyst estimates of $21.53 million. During the same quarter last year, the company posted ($0.22) earnings per share. The business’s revenue was up 20.8% on a year-over-year basis.

A number of equities analysts recently issued reports on the company. Guggenheim reissued a “buy” rating and set a $41.00 price target on shares of Intersect ENT in a report on Friday. Northland Securities reissued a “hold” rating and set a $25.00 price target on shares of Intersect ENT in a report on Friday, November 3rd. Piper Jaffray Companies reissued a “buy” rating and set a $35.00 price target on shares of Intersect ENT in a report on Tuesday, August 22nd. Zacks Investment Research raised Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a report on Thursday, October 5th. Finally, BidaskClub lowered Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $33.38.

In related news, General Counsel David Aaron Lehman sold 36,000 shares of the firm’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $32.75, for a total value of $1,179,000.00. Following the completion of the sale, the general counsel now owns 45,000 shares in the company, valued at $1,473,750. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Frederic H. Moll sold 6,700 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $28.77, for a total transaction of $192,759.00. Following the completion of the sale, the director now owns 247,124 shares of the company’s stock, valued at approximately $7,109,757.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 129,838 shares of company stock valued at $3,892,610. 13.70% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of the company. FMR LLC lifted its position in shares of Intersect ENT by 247.7% during the 2nd quarter. FMR LLC now owns 1,482,909 shares of the medical equipment provider’s stock valued at $41,447,000 after acquiring an additional 1,056,389 shares during the period. Vanguard Group Inc. lifted its position in shares of Intersect ENT by 6.7% during the 2nd quarter. Vanguard Group Inc. now owns 1,139,623 shares of the medical equipment provider’s stock valued at $31,853,000 after acquiring an additional 71,750 shares during the period. Alliancebernstein L.P. lifted its position in shares of Intersect ENT by 2,746.9% during the 2nd quarter. Alliancebernstein L.P. now owns 931,505 shares of the medical equipment provider’s stock valued at $26,036,000 after acquiring an additional 898,785 shares during the period. Neuberger Berman Group LLC lifted its position in shares of Intersect ENT by 8.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 802,521 shares of the medical equipment provider’s stock valued at $24,999,000 after acquiring an additional 59,620 shares during the period. Finally, State Street Corp lifted its position in shares of Intersect ENT by 33.6% during the 2nd quarter. State Street Corp now owns 552,344 shares of the medical equipment provider’s stock valued at $15,437,000 after acquiring an additional 138,968 shares during the period. Institutional investors own 86.31% of the company’s stock.

Intersect ENT (NASDAQ:XENT) traded up $0.25 during midday trading on Friday, hitting $32.10. The company had a trading volume of 245,366 shares, compared to its average volume of 311,529. Intersect ENT has a 52-week low of $11.02 and a 52-week high of $34.40.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Intersect ENT Inc (XENT) Will Announce Earnings of -$0.17 Per Share” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/16/zacks-brokerages-anticipate-intersect-ent-inc-xent-will-announce-earnings-of-0-17-per-share.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Get a free copy of the Zacks research report on Intersect ENT (XENT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.